These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 7796290)

  • 1. Controversies in the treatment of prostate cancer with maximal androgen deprivation.
    McLeod DG; Moul JW
    Surg Oncol Clin N Am; 1995 Apr; 4(2):345-59. PubMed ID: 7796290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hormone therapy of locally advanced and metastatic prostate carcinoma].
    Rübben H
    Praxis (Bern 1994); 2001 Sep; 90(38):1641-4. PubMed ID: 11675917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer.
    Siddiqui SA; Boorjian SA; Blute ML; Rangel LJ; Bergstralh EJ; Karnes RJ; Frank I
    BJU Int; 2011 Feb; 107(3):383-8. PubMed ID: 21265985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant and neoadjuvant therapies in high risk localized prostate cancer.
    Giannakopoulos X; Stagikas D; Charalabopoulos A; Sofikitis N; Charalabopoulos K
    J Exp Clin Cancer Res; 2006 Dec; 25(4):469-73. PubMed ID: 17310835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor.
    Grossfeld GD; Li YP; Lubeck DP; Broering JM; Mehta SS; Carroll PR
    J Urol; 2002 Aug; 168(2):530-5. PubMed ID: 12131303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant therapy for prostate cancer patients at high risk of recurrence following radical prostatectomy.
    Andriole GL
    Eur Urol; 1997; 32 Suppl 3():65-9. PubMed ID: 9267788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Is maximal androgenic blockade necessary in the treatment of prostatic cancer?].
    Matveev BP; Bukharkin BV
    Urologiia; 2003; (6):6-10. PubMed ID: 14708235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy.
    Van Poppel H; Joniau S; Van Cleynenbreugel B; Mottaghy FM; Oyen R
    Prostate Cancer Prostatic Dis; 2009; 12(2):116-23. PubMed ID: 19238169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer.
    Hennenfent BR
    Br J Urol; 1998 Jul; 82(1):166. PubMed ID: 9698691
    [No Abstract]   [Full Text] [Related]  

  • 12. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
    Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
    J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate specific antigen doubling time after radical prostatectomy: effect of neoadjuvant androgen deprivation therapy.
    Rabbani F; Perrotti M; Bastar A; Fair WR
    J Urol; 1999 Mar; 161(3):847-52. PubMed ID: 10022699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant total androgen suppression and radiotherapy in the management of locally advanced prostate cancer.
    Roach M
    Semin Urol Oncol; 1996 May; 14(2 Suppl 2):32-7; discussion 38. PubMed ID: 8725889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer.
    Wieder JA; Soloway MS
    J Urol; 1998 Aug; 160(2):299-315. PubMed ID: 9679867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer: non-metastatic.
    Wilt T
    Clin Evid; 2002 Jun; (7):812-23. PubMed ID: 12230707
    [No Abstract]   [Full Text] [Related]  

  • 17. Neoadjuvant hormonal treatment prior to radical prostatectomy: facts and open questions.
    Schulman CC; Wildschutz T; Zlotta AR
    Eur Urol; 1997; 32 Suppl 3():41-7. PubMed ID: 9267784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
    Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M
    Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormonal manipulation for rising PSA after radical prostatectomy.
    Bhayani SB; Andriole GL
    Semin Urol Oncol; 1999 Aug; 17(3):148-53. PubMed ID: 10462318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
    Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
    Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.